0KCC.LSE Insight Molecular Diagnostics

Healthcare Commercial Services & Supplies London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0KCC.LSE undervalued?

Graham number

The Graham number of Insight Molecular Diagnostics cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Insight Molecular Diagnostics fundamental analysis

No fundamental analysis for Insight Molecular Diagnostics yet.

Insight Molecular Diagnostics stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Insight Molecular Diagnostics

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immun…

Full company profile